Gene therapy for malignant mesothelioma: current prospects and challenges (Q38079969)

28 August 2017

Gene therapy for malignant mesothelioma: current prospects and challenges (English)

1 reference

28 August 2017

0 references

M Tagawa

1

1 reference

28 August 2017

Y Tada

series ordinal

2

1 reference

28 August 2017

H Shimada

series ordinal

3

1 reference

28 August 2017

K Hiroshima

series ordinal

4

1 reference

28 August 2017

8 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

20

1 reference

28 August 2017

3

1 reference

28 August 2017

150-156

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2013.1

28 August 2017

0 references

cites work

The pathogenesis of mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Erionite exposure in North Dakota and Turkish villages with mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Update on the molecular biology of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

CD46 is a cellular receptor for group B adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Cancer therapy with local oncolysis and topical cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

21 January 2018

Malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2013.1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2013.1

1 reference

28 August 2017

1 reference